Providers

Previous research has shown the health effects of obesity, including the decline in lung function. New research highlights obesity is a risk factor for asthma and chronic obstructive pulmonary disease in premenopausal and postmenopausal women.

Studies focused on Asian populations with pulmonary arterial hypertension (PAH) treated with sildenafil are rare, and a new meta-analysis has found the phosphodiesterase-5 inhibitor effective in this understudied subgroup.

The redesigned accountable care organization (ACO) model is called the Realizing Equity, Access, and Community Health model and is scheduled to begin in 2023.

In this National Press Club address, American Medical Association President Gerald E Harmon, MD, outlines what steps need to be taken to better prepare the nation for the next pandemic.

Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the efficacy of biologics in the treatment of atopic dermatitis and other recently approved therapeutics.

Adalimumab and infliximab were the most common biologic therapies associated with the onset of palmoplantar pustulosis and palmoplantar pustular psoriasis.

The representation of Black physicians is alarmingly low, but the opportunities for change are possible and urgent. Health care leaders and human resource departments need to address these disparities, and increasing diversity among their workforce is an excellent place to begin.

Access to digital health tools to improve patient outcomes and quality of life are lacking among patients with multiple myeloma (MM) who are elderly, at risk of relapse, or live in rural communities, suggesting more tools and guidelines are needed for these populations.

Jacob Sands, MD, who leads the small cell lung cancer research program at Dana-Farber Cancer Institute, speaks with The American Journal of Managed Care (AJMC®) about the need for more patients who meet the criteria for lung screening to catch cancer before it reaches an advanced stage.

Drugs targeting FGFR mutations, which are seen in patients with intrahepatic cholangiocarcinoma (CCA), have generated particular excitement; the authors note that prior to the approval of pemigatinib, the first targeted therapy approved by FDA, only 15% to 25% of patients with CCA were “fit enough to receive second-line chemotherapy.”

Robert Sidbury, MD, MPH, chief of the Division of Dermatology at Seattle Children's Hospital, discusses risk factors involved in the pathogenesis of atopic dermatitis and several diagnostic methods.

Immunoglobulins, free light chains, and beta-2 microglobulin all show promise in tracking systemic lupus erythematosus (SLE) and other autoimmune diseases.

AHIP released a report looking at the price markups for 10 drugs that can be delivered more affordably through specialty pharmacies, including 3 drugs with multiple biosimilars available.

Asthma, aspirin-exacerbated respiratory disease, and nasal cytology were identified as predictors of chronic rhinosinusitis with nasal polyps recurrence.

A JAMA Dermatology study found that greater exposure to air pollutants, such as carbon monoxide and fine particulate matter, were significantly associated with later psoriasis flares.

The president’s aim is a 50% reduction in age-adjusted cancer deaths by 2047. This goal seems audacious, but it is likely achievable.

High-risk patients and patients with a history of pulmonary arterial hypertension (PAH) had significantly different cytokine profiles compared with patients with a low risk of the condition.

The National Clinical Care Commission (NCCC) issued 39 recommendations to improve diabetes prevention and care in the United States.

Lessons from the early days of chimeric antigen receptor (CAR) T-cell therapy remain fresh as Kite Pharma prepares for the FDA to act on its supplemental biologics license application for use of axi-cel as second-line therapy in relapsed or refractory large B-cell lymphoma. A target action date is set for April 1, 2022.

Risankizumab was shown to be highly effective in patients with moderate to severe psoriasis of tertiary medical centers in Italy, in which response was found to be significantly affected by smoking, and incidence of psoriatic arthritis.

A statement from NCCN’s Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis said that the panel “endorses vaccination for all eligible persons based on FDA-approved indications or emergency use authorization” and emphasized the need for everyone to be fully vaccinated—including third doses.

Children with moderate to severe atopic dermatitis were found to be more likely to report suboptimal sleep and attention regulation outcomes.

This new study from investigators at University of Calgary investigated the potential of midwall striae fibrosis to predict hospital admission for heart failure.

More patients with moderate-to-severe psoriasis were found to be early responders to ixekizumab vs ustekinumab; all those who achieved early response were associated with stable skin clearance long-term.

Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the inflammatory mechanisms of atopic dermatitis and risk of comorbidities in affected patients.

This new analysis of more than 11 million veterans investigated risks of several cardiovascular diseases beyond the first 30 days after COVID-19 infection.

Researchers reviewed advances in the management of chronic rhinosinusitis, with and without nasal polyps, from 2020 to 2021.

Patients with chronic rhinosinusitis with nasal polyps who had elevated serum amyloid A (SAA) levels were more likely to achieve disease-controlled status vs those with low SAA levels after endoscopic sinus surgery.

Cardinal Health's report, “2022 Biosimilars Report: The U.S. Journey and Path Ahead,” outlines how biosimilars will move beyond their comfort zones in oncology and rheumatology and more boldly into therapeutic areas such as ophthalmology and diabetes care.

A study from investigators at Fox Chase Cancer Center sought comparative outcomes data on adverse reactions from COVID-19 vaccination among patients with a history of cancer and those undergoing treatment and found equivalent safety outcomes.